Amgen (AMGN) Earnings Buzz Builds, Is The Stock Already Overvalued?

Amgen's stock closed at $366.29, drawing investor attention after a recent streak of earnings surprises and a 7.21% gain over the past month. The most-followed Simply Wall St narrative values AMGN at $352 (about 4% overvalued), citing earnings forecasts and a future P/E of 24.2x, while the platform's DCF model implies a much higher fair value of $687.78.

Why it matters: Bulls highlight a late-stage pipeline including MariTide for obesity/type 2 diabetes and cardiovascular and oncology assets, while bears warn of drug pricing pressure and biosimilar competition that could challenge margins.